Study guide
10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding
Key Takeaways Explain This Topic AI
NOWS results from the abrupt cessation of transplacental opioid transfer at delivery, causing noradrenergic/cholinergic storm with CNS irritability, autonomic hyperactivity, and GI dysfunction.
The Eat, Sleep, Console (ESC) functional assessment model evaluates eating ≥1 oz, sleeping undisturbed ≥1 hour, and consoling within 10 minutes, cutting pharmacotherapy rates from >50% to <15%.
Non-pharmacological interventions—especially rooming-in, skin-to-skin contact, swaddling, and low-stimulation environments—form the mandatory first-line foundation before medication.
When functional impairment persists despite non-pharmacological optimization, first-line pharmacotherapy utilizes oral morphine or oral methadone, with clonidine as an adjunctive agent.
Breastfeeding is strongly recommended for mothers on stable methadone or buprenorphine who are HIV-negative and free of illicit use; milk contains <1-3% of maternal dose and significantly attenuates NOWS.
Last updated: September 2026
Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding
Neonatal Opioid Withdrawal Syndrome (NOWS)—historically encompassed under the broader designation of Neonatal Abstinence Syndrome (NAS)—is an expected, treatable constellation of neurochemical and physiological signs that occurs in neonates following chronic in utero exposure to opioids. For the Advanced Practice Registered Nurse specializing in addictions (CARN-AP), mastering NOWS involves understanding its molecular pathophysiology, driving the paradigm shift from subjective sign-scoring to functional assessment, implementing evidence-based non-pharmacological care, directing judicious pharmacotherapy, and championing maternal-infant bonding through breastfeeding.
Pathophysiology and Neurobiology of NOWS
During gestation, exogenous opioids cross the placental barrier with ease due to their lipophilicity and low molecular weight, entering fetal circulation and binding to fetal central mu-opioid receptors. The continuous presence of opioids suppresses fetal neuronal excitability and inhibits adenylyl cyclase activity, reducing intracellular cyclic adenosine monophosphate (cAMP). MOLECULAR PATHOPHYSIOLOGY OF NOWS
- IN UTERO (Chronic Exposure): Continuous Mu-Receptor Agonism
- > Compensatory Up-regulation of Adenylyl Cyclase
- > Increased Intracellular cAMP Machinery
- ----------------------------------------
- DELIVERY (Cord Clamping): ABRUPT CESSATION OF OPIOID SUPPLY
- > Severe Central Mu-Receptor Uncoupling
- > Massive Disinhibition of Locus Coeruleus
- > Unchecked Norepinephrine / Dopamine Storm
- > Excessive Acetylcholine & Serotonin Flux
- ----------------------------------------
- CLINICAL SYNDROME: CNS Irritability + Autonomic Crisis + GI Spasm
Upon delivery and cord clamping, the continuous transplacental supply of opioids terminates instantly. The neonate clears the remaining drug through immature hepatic glucuronidation (primarily UGT2B7) and developing renal excretion. As opioid receptor occupancy rapidly falls, the homeostatically up-regulated adenylyl cyclase cascade rebounds uncontrollably. This triggers a catastrophic noradrenergic and cholinergic storm emanating from the pontine locus coeruleus , precipitating the multi-system clinical manifestation of NOWS.
Clinical Manifestations: The Classic Triad
NOWS signs manifest across three distinct physiological organ systems:
Central Nervous System (CNS) Irritability: High-pitched, inconsolable crying; fragmented sleep; coarse tremors (both when disturbed and undisturbed); exaggerated Moro reflex; hypertonia; facial excoriation (from friction against bedding); and, in rare severe untreated cases, generalized myoclonic seizures.
Autonomic Rebound & Dysregulation: Tachypnea (>60 breaths/min); hyperthermia; profuse sweating (diaphoresis); frequent yawning (>3-4 times per cluster); frequent sneezing; nasal stuffiness; and cutaneous mottling.
Gastrointestinal (GI) Dysfunction: Uncoordinated suck and swallow reflexes; voracious hunger paired with poor caloric retention; frequent regurgitation and projectile vomiting; loose, watery, explosive diarrhea; severe perianal excoriation; and rapid weight loss exceeding standard physiological limits (>10% of birth weight).
Timeline of Withdrawal Across Opioid Agents
The timing of withdrawal onset reflects the elimination half-life and active metabolites of the maternal substance:
Short-acting opioids (heroin, immediate-release oxycodone): Signs emerge rapidly within 24 to 48 hours post-delivery.
Buprenorphine: Signs typically peak between 36 to 72 hours , occasionally up to Day 4-5.
Methadone: Due to prolonged tissue accumulation and elimination kinetics, onset is delayed to 48 to 72 hours or longer (frequently peaking on Days 4 to 6). Neonates exposed to methadone require observed hospital monitoring for a minimum of 4 to 7 days before safe discharge.
Assessment Paradigms: Modified Finnegan (FNASS) vs. Eat, Sleep, Console (ESC)
Historically, the clinical management of NAS was governed by the Modified Finnegan Neonatal Abstinence Scoring System (FNASS) , developed in 1975. Over the last decade, high-quality multi-center research has driven a nationwide transformation toward the Eat, Sleep, Console (ESC) functional assessment approach. +---------------------------------------------------------------------------------------------------------+
- | FINNEGAN SCORING (FNASS) vs. EAT, SLEEP, CONSOLE (ESC) |
- +------------------------------------+--------------------------------------------------------------------+
- | Assessment Dimension | FNASS (Legacy Paradigm) | ESC (Modern Functional Standard) |
- +------------------------------------+-----------------------------------+--------------------------------+
- | Conceptual Focus | Quantification of individual | Functional infant well-being and |
- | | physical withdrawal signs | core biological activities |
- | Number of Evaluated Items | 21 discrete physical signs | 3 primary functional domains |
- | Primary Setting of Care | NICU / Special Care Nursery | Rooming-in with parents / Postpartum |
- | Pharmacotherapy Trigger | Arbitrary score (≥8 x3 or ≥12 x2) | Failure to Eat, Sleep, or Console |
- | | regardless of infant comfort | despite maximal non-pharm interventions|
- | Neonatal Pharmacotherapy Rates | High (>50% to 80% of infants) | Low (<10% to 15% of infants) |
- | Average Hospital Length of Stay | Prolonged (18 to 25+ days) | Slashed (5 to 8 days) |
- | Family Involvement | Passive observers; frequent | Parents are primary caregivers and |
- | | separation from neonate | essential partners in soothing |
- +------------------------------------+-----------------------------------+--------------------------------+
- Limitations and Pitfalls of the Finnegan Scale
Subjectivity and Variance: The 21-item scale includes highly subjective criteria (e.g., "mild vs. severe tremors", "hyperactive Moro reflex"), resulting in immense inter-rater variability between nurses.
Over-Medicalization: Benign physiological responses (e.g., sneezing, yawning, mild mottling) accumulate points that push infants over the arbitrary threshold (scores ≥ 8 \ge 8 ≥ 8 on three consecutive evaluations or ≥ 12 \ge 12 ≥ 12 on two consecutive evaluations).
Maternal-Infant Disruption: High Finnegan scores routinely triggered immediate transfer to the Neonatal Intensive Care Unit (NICU), separating the infant from the mother, destroying early breastfeeding routines, and inducing profound parental guilt.
The Eat, Sleep, Console (ESC) Functional Framework
Developed by Grossman and colleagues at Yale-New Haven Children's Hospital and validated in a landmark NEJM clinical trial (Grossman et al., NEJM , 2023), the Eat, Sleep, Console (ESC) model abandons arbitrary numerical sign counts in favor of evaluating functional impairment . THE THREE PILLARS OF ESC EVALUATION
1. EAT: Can the infant feed adequately for gestational age?
- >=1 oz (30 mL) of formula per feed, OR
- Effective, coordinated breastfeeding for >=10-15 minutes
2. SLEEP: Can the infant sleep undisturbed for at least 1 hour?
- Undisturbed sleep >=1 hour between feedings without distress
3. CONSOLE: Can the infant be consoled within 10 minutes?
- If crying, can the caregiver console the infant in <=10 minutes
using standard non-pharmacological soothing steps?
The ESC Huddle and Stepped Care
Under ESC, when an infant struggles in any domain (e.g., sleeping <1 hour or requiring >10 minutes to console), it does not automatically trigger medication. Instead, it triggers an "ESC Huddle" involving the bedside nurse, provider, and parents. The team asks: "Are non-pharmacological measures optimized?"
Has the infant been held skin-to-skin?
Is the room quiet and dark?
Is the infant swaddled snugly?
Has a small-volume feeding or non-nutritive sucking been offered?
Medication is reserved exclusively for infants whose functional failure persists after maximal non-pharmacological support is exhausted.
First-Line Non-Pharmacological Interventions: Centering the Family
Non-pharmacological care is not merely supportive—it is the primary therapeutic intervention for NOWS. Effective non-pharmacological protocols significantly reduce autonomic hyperactivity and prevent the need for opioid pharmacotherapy.
Rooming-In (The Most Powerful Modality): Keeping the mother and infant together 24 hours a day in a private room is the single most effective intervention in perinatal addiction. Rooming-in reduces the need for neonatal pharmacotherapy by over 70% , prevents NICU admission, and significantly shortens hospital length of stay. The mother's familiar voice, heartbeat, and scent provide direct neurological down-regulation of the infant's hyperactive locus coeruleus.
Skin-to-Skin Contact (Kangaroo Care): Direct maternal-infant skin-to-skin contact stabilizes infant body temperature, regularizes heart and respiration rates, promotes deep sleep, lowers infant cortisol levels, and stimulates maternal oxytocin release, which enhances milk production.
Low-Stimulation Sensory Environment: The infant's central nervous system is acutely hyperexcitable. The clinical environment must provide dimmed lighting, minimal auditory stimuli, soft voices, and clustered nursing care to avoid startling or overwhelming the neonate.
Swaddling and Gentle Positioning: Tight swaddling with hands positioned at the midline prevents flailing, dampens hyperactive startle reflexes, and fosters neuromuscular organization. Gentle vertical rocking or rhythmic swaying soothes dysregulated vestibular pathways.
Frequent, Low-Volume Feedings: NOWS infants experience rapid gut motility and hypermetabolism. Offering frequent, smaller feeds (on-demand or every 2-3 hours) prevents gastric overdistension, decreases vomiting, and satisfies the infant's intense, uncoordinated urge to suck. High-calorie formulas (22-24 kcal/oz) can be utilized if poor weight gain persists.
Pharmacological Management Protocols
Pharmacotherapy is indicated only when an infant exhibits persistent functional deficits (severe inability to eat, sleep <1 hour, or inconsolability >10 minutes) despite rigorous, documented non-pharmacological optimization, or when severe complications arise (e.g., seizures, intractable vomiting with dehydration). +---------------------------------------------------------------------------------------------------------+
- | NOWS PHARMACOTHERAPY COMPARISON PANEL |
- +-------------------+----------------------------+-----------------------+--------------------------------+
- | Medication | Standard Clinical Regimen | Advantages | Clinical Caveats / Monitoring |
- +-------------------+----------------------------+-----------------------+--------------------------------+
- | Oral Morphine | 0.04 to 0.08 mg/kg/dose PO | Rapid onset; easily | Short half-life requires q3-4h |
- | Solution (1st-line| q3-4h; titrated in small | titrated and weaned; | dosing; peak-and-trough |
- | standard) | increments based on ESC | familiar in nurseries | fluctuations in plasma levels |
- +-------------------+----------------------------+-----------------------+--------------------------------+
- | Oral Methadone | 0.05 to 0.1 mg/kg/dose PO | Long elimination t1/2;| Slower titration kinetics; |
- | Solution (1st-line| q6-12h; weaned slowly by | smoother steady-state | accumulation risk; QTc |
- | alternative) | 10-20% per day | without troughs | monitoring rarely required |
- +-------------------+----------------------------+-----------------------+--------------------------------+
- | Oral Clonidine | 0.5 to 1.0 mcg/kg/dose PO | Non-opioid; suppresses| Monitor for bradycardia and |
- | (2nd-line / | q4-6h (adjunct to morphine | central noradrenergic | hypotension; must be weaned |
- | adjunct) | or methadone) | storm without sedation| to prevent rebound hypertension|
- +-------------------+----------------------------+-----------------------+--------------------------------+
- | Phenobarbital | Loading: 16-20 mg/kg; | Non-opioid sedative; | Narrow therapeutic window; |
- | (Adjunct for | Maintenance: 3-5 mg/kg/day | covers concurrent | profound sedation disrupts |
- | polysubstance) | divided q12h | sedative/benzo misuse | feeding; interferes with ESC |
- +-------------------+----------------------------+-----------------------+--------------------------------+
First-Line Opioid Agonist Replacement: Oral morphine solution is the historical standard, titrated in 0.02 mg/kg increments until functional eating, sleeping, and consoling are restored. Oral methadone solution is an increasingly favored first-line alternative due to its prolonged half-life, allowing q8-12h dosing and eliminating the peak-and-trough withdrawal swings seen with morphine.
Adjunctive Clonidine: As an alpha-2 adrenergic agonist, clonidine directly stimulates presynaptic inhibitory autoreceptors in the locus coeruleus, shutting down excessive norepinephrine release. Adding clonidine reduces total opioid exposure, shortens weaning time, and controls autonomic signs without causing central respiratory depression.
Breastfeeding on MOUD: Evidence, Guidelines & Contraindications
The American Academy of Pediatrics (AAP), ACOG, and ASAM strongly encourage exclusive breastfeeding for mothers maintained on stable MOUD (methadone or buprenorphine).
Clinical and Pharmacokinetic Rationale
Negligible Drug Concentrations in Human Milk: Both methadone and buprenorphine transfer into maternal breast milk in exceptionally small amounts. The calculated infant weight-adjusted relative dose is less than 1% to 3% of the maternal dose—concentrations far too low to produce direct sedation or respiratory compromise.
Profound Attenuation of NOWS Severity: Breastfeeding delivers small, continuous micro-doses of opioids that gently taper the infant, significantly lowering peak withdrawal severity. Breastfed infants have significantly lower rates of pharmacotherapy , shorter hospital lengths of stay, and require lower doses of morphine if treated.
Neurodevelopmental and Maternal Benefits: Breastfeeding facilitates skin-to-skin bonding, enhances maternal confidence, reduces postpartum depression, and empowers women in recovery as essential healers of their infants.
Maternal Eligibility Criteria for Breastfeeding
Breastfeeding is strongly encouraged when the following criteria are met:
The mother is enrolled and compliant in an evidence-based substance use treatment program.
The mother has been clinically stable on a consistent dose of methadone or buprenorphine.
The mother has been abstinent from non-prescribed opioids and illicit substances (verified by clinical assessment and toxicology testing) for at least 30 to 90 days prior to delivery.
The mother is confirmed HIV-negative (in resource-rich settings, maternal HIV infection remains a strict contraindication to breastfeeding due to vertical transmission risk).
The mother has no active, unmanaged Hepatitis C-induced bleeding/cracked nipples or active herpes simplex breast lesions.